Fatemeh Kheradmand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fatemeh Kheradmand has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Yousef Rasmi
Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
11 shared publications - Anahita Fathi Azarbayjani
Experimental and Applied Pharmaceutical Research Center, Urmia University of Medical Sciences, Urmia, Iran
4 shared publications Somayeh Atari-Hajipirloo
Epartment of biochemistry, Faculty of Medicine, Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran
4 shared publications- Alireza Shirpoor
Department of Physiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
3 shared publications - Mahshid Mohammadian
Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
3 shared publications - Mohammad Hassan Khadem-Ansari
Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
3 shared publications
Latest Publications
- 20 May 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198 (8) , 6173-6192
Menstrual Blood Stem Cell-Derived Exosomes as Modulators of Apoptosis, Migration and Angiogenesis in Breast Cancer Cells
The complexity of breast cancer cells complicates the process of enhancing our understanding, which may lead to the development of effective therapeutic agents and approaches. Among the novel medical interventions, menstrual blood-derived mesenchymal stem cells (Mens-MSCs) demonstrate proactive and immunomodulatory interactions with malignant cells. This study aims to evaluate the effects of Mens-MSCs-derived exosomes (MM-Exos) on breast cancer cell behaviors, with particular emphasis on apoptosis, migration, and angiogenesis. MM-Exos were characterized using DLS, flow cytometry, and TEM. After determining the effective concentration by MTT assay, the exosomes were applied to MDA-MB-231 and SK-BR-3 cell lines. Cell motility was evaluated using a scratch assay, while apoptosis, cell cycle distribution, and ROS generation were assessed by flow cytometry and ELISA. Gene expression of BAX, BCL-2, MMP-2, and VEGF was analyzed by qPCR, and corresponding protein levels were confirmed through Western blotting. Based on the results, MM-Exos dose-dependently decreased breast cancer cell survival across both cell lines. Furthermore, MM-Exos at 50 and 100 µg/ml significantly reduced the migratory rate of cell lines (P < 0.001). Treatment with MM-Exos (100 µg/ml) significantly increased ROS production (P < 0.001), enhanced apoptosis (P < 0.001), induced cell cycle arrest (P < 0.001), and altered gene and protein expression. Both cell lines exhibited significant down-regulation of VEGF(P < 0.001), BCL-2 (P < 0.01), and MMP-2 (P < 0.01) after treatment with MM-Exos, whereas BAX demonstrated significant up-regulation (P < 0.001). Based on results, MM-Exo demonstrates anticancer functions by enhancing cytotoxicity, ROS generation, apoptosis, while reducing migration rate. Thus, MM-Exo may represent a potential therapeutic option for breast cancer; however, further comprehensive studies are required.
- 20 May 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198 (8) , 6173-6192
Menstrual Blood Stem Cell-Derived Exosomes as Modulators of Apoptosis, Migration and Angiogenesis in Breast Cancer Cells
The complexity of breast cancer cells complicates the process of enhancing our understanding, which may lead to the development of effective therapeutic agents and approaches. Among the novel medical interventions, menstrual blood-derived mesenchymal stem cells (Mens-MSCs) demonstrate proactive and immunomodulatory interactions with malignant cells. This study aims to evaluate the effects of Mens-MSCs-derived exosomes (MM-Exos) on breast cancer cell behaviors, with particular emphasis on apoptosis, migration, and angiogenesis. MM-Exos were characterized using DLS, flow cytometry, and TEM. After determining the effective concentration by MTT assay, the exosomes were applied to MDA-MB-231 and SK-BR-3 cell lines. Cell motility was evaluated using a scratch assay, while apoptosis, cell cycle distribution, and ROS generation were assessed by flow cytometry and ELISA. Gene expression of BAX, BCL-2, MMP-2, and VEGF was analyzed by qPCR, and corresponding protein levels were confirmed through Western blotting. Based on the results, MM-Exos dose-dependently decreased breast cancer cell survival across both cell lines. Furthermore, MM-Exos at 50 and 100 µg/ml significantly reduced the migratory rate of cell lines (P < 0.001). Treatment with MM-Exos (100 µg/ml) significantly increased ROS production (P < 0.001), enhanced apoptosis (P < 0.001), induced cell cycle arrest (P < 0.001), and altered gene and protein expression. Both cell lines exhibited significant down-regulation of VEGF(P < 0.001), BCL-2 (P < 0.01), and MMP-2 (P < 0.01) after treatment with MM-Exos, whereas BAX demonstrated significant up-regulation (P < 0.001). Based on results, MM-Exo demonstrates anticancer functions by enhancing cytotoxicity, ROS generation, apoptosis, while reducing migration rate. Thus, MM-Exo may represent a potential therapeutic option for breast cancer; however, further comprehensive studies are required.
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Research in Pharmaceutical Sciences
- Vol. 20 (1) , 77-94
Dietary silymarin supplementation enhances chemotherapy efficacy of capecitabine and irinotecan and mitigates hepatotoxicity in a mouse model of colon cancer
Background and purpose: The flavonoid silymarin (SMN) has shown promise due to its antioxidant, anti-inflammatory, and anticancer properties. SMN has been widely used in preclinical and clinical studies to treat various types of cancer, alone and with chemotherapy agents. Recent research suggests that SMN may increase conventional chemotherapy efficacy and reduce adverse effects. Herein, we investigated the therapeutic efficacy of SMN and its combination with capecitabine (CAP) and irinotecan (IRI) in a mouse model of colon cancer. Experimental approach: Following 1,2 dimethylhydrazine-induced colon cancer, a modified diet supplemented with SMN (2500 ppm) and mono- and combined therapy of CAP and IRI was used. Serum samples were analyzed for lipid profile, liver function, and inflammatory cytokines. Oxidative stress and inflammation markers, including malondialdehyde (MDA), nitric oxide (NO), myeloperoxidase (MPO), superoxide dismutase (SOD), and glutathione peroxidase (GPx) were measured in colonic, hepatic, and circulatory samples. Colonic BAX and Bcl-2 levels were examined via western blotting and histopathological analysis of colon sections was conducted. Findings/Results: SMN alone and combined with chemotherapeutic agents significantly mitigated the elevated inflammatory cytokines liver function enzyme levels, and hyperlipidemia. Furthermore, SMN supplementation with chemotherapy agents enhanced antioxidant activity and reduced lipid peroxidation and inflammatory markers. Significant upregulation of BAX and downregulation of Bcl-2 were observed. In addition, treatment regimens ameliorated carcinogen-induced polyp multiplicity, adenoma formation, dysplastic changes, and lymphocytic aggregation. Conclusion and implications: Our results demonstrated that the potential anticancer properties of SMN could enhance chemotherapy efficacy and reduce carcinogen- and chemotherapy-induced hepatotoxicity.
- 1 January 2025
- Published by Wolters Kluwer Health in Research in Pharmaceutical Sciences
- Vol. 20 (1) , 77-94
Open AccessDietary silymarin supplementation enhances chemotherapy efficacy of capecitabine and irinotecan and mitigates hepatotoxicity in a mouse model of colon cancer
Background and purpose: The flavonoid silymarin (SMN) has shown promise due to its antioxidant, anti-inflammatory, and anticancer properties. SMN has been widely used in preclinical and clinical studies to treat various types of cancer, alone and with chemotherapy agents. Recent research suggests that SMN may increase conventional chemotherapy efficacy and reduce adverse effects. Herein, we investigated the therapeutic efficacy of SMN and its combination with capecitabine (CAP) and irinotecan (IRI) in a mouse model of colon cancer. Experimental approach: Following 1,2 dimethylhydrazine-induced colon cancer, a modified diet supplemented with SMN (2500 ppm) and mono- and combined therapy of CAP and IRI was used. Serum samples were analyzed for lipid profile, liver function, and inflammatory cytokines. Oxidative stress and inflammation markers, including malondialdehyde (MDA), nitric oxide (NO), myeloperoxidase (MPO), superoxide dismutase (SOD), and glutathione peroxidase (GPx) were measured in colonic, hepatic, and circulatory samples. Colonic BAX and Bcl-2 levels were examined via western blotting and histopathological analysis of colon sections was conducted. Findings/Results: SMN alone and combined with chemotherapeutic agents significantly mitigated the elevated inflammatory cytokines liver function enzyme levels, and hyperlipidemia. Furthermore, SMN supplementation with chemotherapy agents enhanced antioxidant activity and reduced lipid peroxidation and inflammatory markers. Significant upregulation of BAX and downregulation of Bcl-2 were observed. In addition, treatment regimens ameliorated carcinogen-induced polyp multiplicity, adenoma formation, dysplastic changes, and lymphocytic aggregation. Conclusion and implications: Our results demonstrated that the potential anticancer properties of SMN could enhance chemotherapy efficacy and reduce carcinogen- and chemotherapy-induced hepatotoxicity.
- 29 November 2023
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 33 (2) , 193-199
Assessing evening primrose oil effects on the serum levels of omentin-1 and biochemical parameters in the diabetic rat model
- 29 November 2023
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 33 (2) , 193-199
Assessing evening primrose oil effects on the serum levels of omentin-1 and biochemical parameters in the diabetic rat model
- Open Access
The Potential Preventive and Therapeutic Roles of NSAIDs in Prostate Cancer
Prostate cancer (PC) is the second most common type of cancer and the leading cause of death among men worldwide. Preventing the progression of cancer after treatments such as radical prostatectomy, radiation therapy, and hormone therapy is a major concern faced by prostate cancer patients. Inflammation, which can be caused by various factors such as infections, the microbiome, obesity and a high-fat diet, is considered to be the main cause of PC. Inflammatory cells are believed to play a crucial role in tumor progression. Therefore, nonsteroidal anti-inflammatory drugs along with their effects on the treatment of inflammation-related diseases, can prevent cancer and its progression by suppressing various inflammatory pathways. Recent evidence shows that nonsteroidal anti-inflammatory drugs are effective in the prevention and treatment of prostate cancer. In this review, we discuss the different pathways through which these drugs exert their potential preventive and therapeutic effects on prostate cancer.
Open AccessThe Potential Preventive and Therapeutic Roles of NSAIDs in Prostate Cancer
Prostate cancer (PC) is the second most common type of cancer and the leading cause of death among men worldwide. Preventing the progression of cancer after treatments such as radical prostatectomy, radiation therapy, and hormone therapy is a major concern faced by prostate cancer patients. Inflammation, which can be caused by various factors such as infections, the microbiome, obesity and a high-fat diet, is considered to be the main cause of PC. Inflammatory cells are believed to play a crucial role in tumor progression. Therefore, nonsteroidal anti-inflammatory drugs along with their effects on the treatment of inflammation-related diseases, can prevent cancer and its progression by suppressing various inflammatory pathways. Recent evidence shows that nonsteroidal anti-inflammatory drugs are effective in the prevention and treatment of prostate cancer. In this review, we discuss the different pathways through which these drugs exert their potential preventive and therapeutic effects on prostate cancer.
- Open Access
- 1 October 2023
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 9 (4) , 193-199
Serum levels of interleukin-10 and its receptor in the multiple myeloma type I patients
Background & Aims: Multiple myeloma is a malignancy of plasma cells that is associated with high morbidity rate. Inflammation is a common feature in malignancy and plays a pivotal role in the cancer pathogenesis. Interleukin-10 is a cytokine with anti-inflammatory properties. The aim of this study was evaluation the importance of interleukin-10 and its ...
- 1 October 2023
- Published by Apex Publishing in Journal of Research in Applied and Basic Medical Sciences
- Vol. 9 (4) , 193-199
Open AccessSerum levels of interleukin-10 and its receptor in the multiple myeloma type I patients
Background & Aims: Multiple myeloma is a malignancy of plasma cells that is associated with high morbidity rate. Inflammation is a common feature in malignancy and plays a pivotal role in the cancer pathogenesis. Interleukin-10 is a cytokine with anti-inflammatory properties. The aim of this study was evaluation the importance of interleukin-10 and its ...
- 17 September 2023
- Published by Elsevier in Life Sciences
- Vol. 332, 122083
Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers
- 17 September 2023
- Published by Elsevier in Life Sciences
- Vol. 332, 122083
Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers
- 16 August 2022
- Published by Springer Nature in Medical Oncology
- Vol. 39 (11) , 1-14
Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells
Hepatocellular carcinoma (HCC), the most prevalent kind of liver cancer, remains one of the world’s main causes of death. The alpha7 nicotinic acetylcholine receptor (α7nAchR) has been recognized to be overexpressed in malignancies and chemoresistance. Since little is known about the role of α7nAchR expression in drug-resistant cells, this study was designed to investigate the effect of α7nAchR suppression in combination with Sorafenib (SOR) on SOR-resistant HCC cells. First, SOR-resistant HCC cells were generated. To suppress the expression of α7nAchR, cells were treated with SOR following siRNA transfection. qRT-PCR was used to examine the expression of α7nAchR and apoptotic genes by evaluating the IC50 of SOR and the combination of α7nAchR siRNA and SOR on the survival of resistant cells. Moreover, apoptosis, autophagy, and cell cycle analysis for resistant HCC cells were performed using flow cytometry. Cell migration and colony formation assays were also used for further confirmation. Our results suggest that inhibiting α7nAchR can lead resistant HCC cells to become sensitive. Furthermore, when siRNA and SOR were treated together, HCC-resistant cells showed a considerable reduction in α7nAchR mRNA gene expression. In addition, when α7nAchR was downregulated in combination with SOR, migration and colony formation were inhibited. Apoptosis was triggered by modulating the expression of apoptotic target genes, and cell cycle arrest was observed in the G2-M and subG1 phases. Overexpression of α7nAchR in SOR-resistant HCC cells suggests that it might be a therapeutic target for HCC cell resistance therapy.
- 16 August 2022
- Published by Springer Nature in Medical Oncology
- Vol. 39 (11) , 1-14
Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells
Hepatocellular carcinoma (HCC), the most prevalent kind of liver cancer, remains one of the world’s main causes of death. The alpha7 nicotinic acetylcholine receptor (α7nAchR) has been recognized to be overexpressed in malignancies and chemoresistance. Since little is known about the role of α7nAchR expression in drug-resistant cells, this study was designed to investigate the effect of α7nAchR suppression in combination with Sorafenib (SOR) on SOR-resistant HCC cells. First, SOR-resistant HCC cells were generated. To suppress the expression of α7nAchR, cells were treated with SOR following siRNA transfection. qRT-PCR was used to examine the expression of α7nAchR and apoptotic genes by evaluating the IC50 of SOR and the combination of α7nAchR siRNA and SOR on the survival of resistant cells. Moreover, apoptosis, autophagy, and cell cycle analysis for resistant HCC cells were performed using flow cytometry. Cell migration and colony formation assays were also used for further confirmation. Our results suggest that inhibiting α7nAchR can lead resistant HCC cells to become sensitive. Furthermore, when siRNA and SOR were treated together, HCC-resistant cells showed a considerable reduction in α7nAchR mRNA gene expression. In addition, when α7nAchR was downregulated in combination with SOR, migration and colony formation were inhibited. Apoptosis was triggered by modulating the expression of apoptotic target genes, and cell cycle arrest was observed in the G2-M and subG1 phases. Overexpression of α7nAchR in SOR-resistant HCC cells suggests that it might be a therapeutic target for HCC cell resistance therapy.
- 1 March 2021
- Published by Maad Rayan Publishing Company in ImmunoAnalysis
- Vol. 1 (1) , 10
Nicotinic Acetylcholine Receptor Subunit Alpha-7 Mediates PD-L1 and CTLA-4 Expression in HepG2 Cells
Background: The liver is the largest solid organ in the body and has several unique immunological roles. The alpha7 subtype of nicotinic acetylcholine receptor (α7nAChR) is expressed in the liver and has different immunoregulatory effects. Programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are two major checkpoints that act as a negative regulator of the immune system. In this study, we examined the effects of activation (with nicotine) and inhibition (with specific siRNA) of α7nAChR on the PD-L1 and CTLA-4 genes expression. Methods: Human hepatocellular carcinoma (HepG2) cell line was used to investigate the effects of treatment with low dose (1 μM) and high dose (10 μM) of nicotine on the PD-L1 and CTLA-4 expression. In addition to this, the effects of treatment with 100 nM concentration of specific siRNA targeting α7nAChR (α7-siRNA) were examined using quantitative real-time PCR. Results: Compared to untreated cells, the HepG2 cells treated with nicotine exhibited significant dose-dependent decreases in PD-L1 expression. Furthermore, nicotine has a biphasic effect on the CTLA-4 expression and decreased its expression in 10 μM concentration. The qRT-PCR revealed that α7-siRNA significantly reduced the mRNA levels of α7nAChR (P < 0.01). Also, compared to control cells, α7-siRNA treated cells exhibited significant increases in both PD-L1 and CTLA-4 expression. Conclusion: These experiments determined that nicotine treatment leads to decreases in PD-L1 and CTLA-4 expression. These effects are reversed by treatment with α7-siRNA, which indicates the involvement of α7nAChR related mechanisms in these processes.
- 1 March 2021
- Published by Maad Rayan Publishing Company in ImmunoAnalysis
- Vol. 1 (1) , 10
Nicotinic Acetylcholine Receptor Subunit Alpha-7 Mediates PD-L1 and CTLA-4 Expression in HepG2 Cells
Background: The liver is the largest solid organ in the body and has several unique immunological roles. The alpha7 subtype of nicotinic acetylcholine receptor (α7nAChR) is expressed in the liver and has different immunoregulatory effects. Programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are two major checkpoints that act as a negative regulator of the immune system. In this study, we examined the effects of activation (with nicotine) and inhibition (with specific siRNA) of α7nAChR on the PD-L1 and CTLA-4 genes expression. Methods: Human hepatocellular carcinoma (HepG2) cell line was used to investigate the effects of treatment with low dose (1 μM) and high dose (10 μM) of nicotine on the PD-L1 and CTLA-4 expression. In addition to this, the effects of treatment with 100 nM concentration of specific siRNA targeting α7nAChR (α7-siRNA) were examined using quantitative real-time PCR. Results: Compared to untreated cells, the HepG2 cells treated with nicotine exhibited significant dose-dependent decreases in PD-L1 expression. Furthermore, nicotine has a biphasic effect on the CTLA-4 expression and decreased its expression in 10 μM concentration. The qRT-PCR revealed that α7-siRNA significantly reduced the mRNA levels of α7nAChR (P < 0.01). Also, compared to control cells, α7-siRNA treated cells exhibited significant increases in both PD-L1 and CTLA-4 expression. Conclusion: These experiments determined that nicotine treatment leads to decreases in PD-L1 and CTLA-4 expression. These effects are reversed by treatment with α7-siRNA, which indicates the involvement of α7nAChR related mechanisms in these processes.
- Open Access
- 1 August 2019
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 9 (3) , 439-444
Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine
Purpose: Dihydropyrimidine dehydrogenase (DPD) is the principal enzyme in the catabolism of fluoropyrimidine drugs including capecitabine. A recent report has suggested that oxaliplatin chemotherapy is associated with elevated DPD levels and chemoresistance pattern. As a newly developed chemotherapeutic agent, 17-allyloamino-17-demethoxy-geldanamycin (17-AAG) can be effective in combination therapy with oxaliplatin and capecitabine in colorectal cancer (CRC). DPD expression level can be a predictive factor in oxaliplatin and capecitabine-based chemotherapy. We evaluated DPD in mRNA and protein levels with new treatments: 17-AAG in combination with oxaliplatin and capecitabine in HT-29 and HCT-116 cell lines. Methods: Drug sensitivity was determined by the water-soluble tetrazolium-1 assay in a previous survey. Then, we evaluated the expression levels of DPD and its relationship with the chemotherapy response in capecitabine, oxaliplatin, and 17-AAG treated cases in single and combination cases in two panels of CRC cell lines. DPD gene and protein expression levels were determined by real-time polymerase chain reaction and western blotting assay, respectively. Results: DPD gene expression levels insignificantly increased in single-treated cases versus untreated controls in both cell lines versus controls. Then, the capecitabine and oxaliplatin were added in double combinations, where DPD gene and protein expression increased in combination cases compared to pre-chemotherapy and single drug treatments. Conclusion: The elevated levels of cytotoxicity in more effective combinations could be related to a different mechanism apart from DPD mediating effects or high DPD level in the remaining resistance cells (drug-insensitive cells), which should be investigated in subsequent studies.
- 1 August 2019
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 9 (3) , 439-444
Open AccessDihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine
Purpose: Dihydropyrimidine dehydrogenase (DPD) is the principal enzyme in the catabolism of fluoropyrimidine drugs including capecitabine. A recent report has suggested that oxaliplatin chemotherapy is associated with elevated DPD levels and chemoresistance pattern. As a newly developed chemotherapeutic agent, 17-allyloamino-17-demethoxy-geldanamycin (17-AAG) can be effective in combination therapy with oxaliplatin and capecitabine in colorectal cancer (CRC). DPD expression level can be a predictive factor in oxaliplatin and capecitabine-based chemotherapy. We evaluated DPD in mRNA and protein levels with new treatments: 17-AAG in combination with oxaliplatin and capecitabine in HT-29 and HCT-116 cell lines. Methods: Drug sensitivity was determined by the water-soluble tetrazolium-1 assay in a previous survey. Then, we evaluated the expression levels of DPD and its relationship with the chemotherapy response in capecitabine, oxaliplatin, and 17-AAG treated cases in single and combination cases in two panels of CRC cell lines. DPD gene and protein expression levels were determined by real-time polymerase chain reaction and western blotting assay, respectively. Results: DPD gene expression levels insignificantly increased in single-treated cases versus untreated controls in both cell lines versus controls. Then, the capecitabine and oxaliplatin were added in double combinations, where DPD gene and protein expression increased in combination cases compared to pre-chemotherapy and single drug treatments. Conclusion: The elevated levels of cytotoxicity in more effective combinations could be related to a different mechanism apart from DPD mediating effects or high DPD level in the remaining resistance cells (drug-insensitive cells), which should be investigated in subsequent studies.